

PET/CT FDG MEDICARE REBATE CRITERIA

Medicare Rebates are available for FDG PET scanning for a series of specific clinical indications. Medicare requirements for accessing these rebates are very specific and can only be claimed when certain clinical conditions are present.

Additionally, for accurate localisation and staging, FDG PET scans often require a Diagnostic CT which should be indicated on the referral.

To assist your understanding of the Medicare Rebate criteria we have summarised the data and provided the specific Medicare Rebate Conditions.

If you have any further queries please do not hesitate to contact your nearest Uniting Care Medical Imaging Clinic.

PET/CT FDG REBATABLE INDICATIONS

REQUEST TYPE	WHO CAN REFER	MEDICARE REQUIRED CRITERIA	FREQUENCY
Single Pulmonary Nodule 61523	Specialist Consultant Physician	Whole body FDG PET study, performed for evaluation of a solitary pulmonary nodule where the lesion is considered unsuitable for transthoracic fine needle aspiration biopsy, or for which an attempt at pathological characterisation has failed.	No defined limit
Non-Small Cell Lung Cancer 61529	Specialist Consultant Physician	Whole body FDG PET study, performed for the staging of proven non-small cell lung cancer, where curative surgery or radiotherapy is planned.	No defined limit
Brain Tumour Recurrent or Malignant 61538	Specialist Consultant Physician	FDG PET study of the brain for evaluation of suspected residual or recurrent malignant brain tumour based on anatomical imaging findings, after definitive therapy (or during ongoing chemotherapy) in patients who are considered suitable for further active therapy.	No defined limit
Colorectal Cancer Metastatic or Recurrent 61541	Specialist Consultant Physician	Whole body FDG PET study, following initial therapy, for the evaluation of suspected residual, metastatic or recurrent colorectal carcinoma in patients considered suitable for active therapy.	No defined limit
Melanoma Metastatic or Recurrent 61553	Specialist Consultant Physician	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected metastatic or recurrent malignant melanoma in patients considered suitable for active therapy.	No defined limit
Epilepsy 61559	Specialist Consultant Physician	FDG PET study of the brain, performed for the evaluation of refractory epilepsy which is being evaluated for surgery.	No defined limit

PET/CT FDG REBATABLE INDICATIONS *continued...*

REQUEST TYPE	WHO CAN REFER	MEDICARE REQUIRED CRITERIA	FREQUENCY
Ovarian Carcinoma Residual, metastatic or recurrent 61565	Specialist Consultant Physician	Whole body FDG PET study, following initial therapy, performed for the evaluation of suspected residual, metastatic or recurrent ovarian carcinoma in patients considered suitable for active therapy.	No defined limit
Uterine Cervix Carcinoma Histologically Proven 61575	Specialist Consultant Physician	Whole body FDG PET study, for the further primary staging of patients with histologically proven carcinoma of the uterine cervix, at FIGO stage IB2 or greater by conventional staging, prior to planned radical radiation therapy or combined modality therapy with curative intent.	No defined limit
Oesophageal or GEJ Carcinoma 61577	Specialist Consultant Physician	Whole body FDG PET study, performed for the staging of proven oesophageal or GEJ carcinoma, in patients considered suitable for active therapy.	No defined limit
Head & Neck Cancer Newly Diagnosed or Recurrent 61598	Specialist Consultant Physician	Whole body FDG PET study performed for the staging of biopsy-proven newly diagnosed or recurrent head and neck cancer.	No defined limit
Head & Neck Cancer Residual 61604	Specialist Consultant Physician	Whole body FDG PET study performed for the evaluation of patients with suspected residual head and neck cancer after definitive treatment, and who are suitable for active therapy.	No defined limit
Squamous Cell Carcinoma 61610	Specialist Consultant Physician	Whole body FDG PET study performed for the evaluation of metastatic squamous cell carcinoma of unknown primary site involving cervical nodes.	No defined limit
Hodgkin or non-Hodgkin Lymphoma Newly Diagnosed 61620	Specialist Consultant Physician	Whole body FDG PET study for the initial staging of newly diagnosed or previously untreated Hodgkin or non-Hodgkin lymphoma.	No defined limit

PET/CT FDG REBATABLE INDICATIONS *continued...*

REQUEST TYPE	WHO CAN REFER	MEDICARE REQUIRED CRITERIA	FREQUENCY
Lymphoma Assessing Treatment 61622	Specialist Consultant Physician	Whole body FDG PET study to assess response to first line therapy either during treatment or within three months of completing definitive first line treatment for Hodgkin or non-Hodgkin lymphoma.	No defined limit
Lymphoma Reoccurrence 61628	Specialist Consultant Physician	Whole body FDG PET study for restaging following confirmation of recurrence of Hodgkin or non-Hodgkin lymphoma.	No defined limit
Lymphoma Second Line Chemotherapy 61632	Specialist Consultant Physician	Whole body FDG PET study to assess response to second-line chemotherapy if haemopoietic stem cell transplantation is being considered for Hodgkin or non-Hodgkin lymphoma.	No defined limit
Sarcoma Initial Staging 61640	Specialist Consultant Physician	Whole body FDG PET study for initial staging of patients with biopsy-proven bone or soft tissue sarcoma (excluding gastrointestinal stromal tumour) considered by conventional staging to be potentially curable.	No defined limit
Sarcoma Residual or Recurrent 61646	Specialist Consultant Physician	Whole body FDG PET study for the evaluation of patients with suspected residual or recurrent sarcoma (excluding gastrointestinal stromal tumour) after the initial course of definitive therapy to determine suitability for subsequent therapy with curative intent.	No defined limit